Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 03, 2025 17:25 ET | Source: Muscular Dystrophy Association

FDA Approves KYGEVVI® (doxecitine and doxribtimine), the First and Only Treatment for Adults and Children Living with Thymidine Kinase 2 deficiency (TK2d), a Rare and Devastating Mitochondrial Disease

New York, Nov. 03, 2025 (GLOBE NEWSWIRE) -- New York, Monday, November 3, 2025 – The Muscular Dystrophy Association (MDA) marks another milestone today in our legacy of progress with the FDA...
November 03, 2025 09:00 ET | Source: Muscular Dystrophy Association

Muscular Dystrophy Association Honors National Family Caregivers Month with Advocacy and Awareness Nationwide

New York, Nov. 03, 2025 (GLOBE NEWSWIRE) -- This November, the Muscular Dystrophy Association (MDA) is honoring family caregivers who provide essential support for people living with muscular...
October 20, 2025 09:00 ET | Source: Muscular Dystrophy Association

Muscular Dystrophy Association Launches Holiday Retail Campaign in Thousands of Retail Locations Nationwide

New York, Oct. 20, 2025 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) today kicked off its largest annual MDA Holiday Retail Campaign, spanning thousands of retail locations...
October 15, 2025 09:00 ET | Source: Muscular Dystrophy Association

Agenda Announced for 2026 MDA Clinical & Scientific Conference Featuring Leading Speakers Dedicated to Groundbreaking Research and Clinical Achievements in Neuromuscular Disease

New York, Oct. 15, 2025 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) today announced the agenda including tracks and chairs for the 2026 MDA Clinical & Scientific Conference...
September 05, 2025 07:00 ET | Source: Entrada Therapeutics, Inc.

Entrada Therapeutics Announces Recipients of Third Annual DREAMS Grant Program

Entrada Therapeutics announces the recipients of its third annual DREAMS Grant Program.
August 25, 2025 09:00 ET | Source: Muscular Dystrophy Association

Muscular Dystrophy Association Launches #MDAstrong Campaign in September During Historic 75th Anniversary, Kicking Off on Labor Day Weekend

New York, Aug. 25, 2025 (GLOBE NEWSWIRE) -- This September, the Muscular Dystrophy Association (MDA) is launching its milestone #MDAstrong campaign during a historic moment for the organization: its...
August 23, 2025 16:42 ET | Source: Muscular Dystrophy Association

Muscular Dystrophy Association and Parent Project Muscular Dystrophy Announce Joint Consensus Guidelines for Safe and Equitable Delivery of Gene Therapy in Duchenne Muscular Dystrophy

New York, Aug. 23, 2025 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) and Parent Project Muscular Dystrophy (PPMD) today announced the publication of jointly developed consensus...
August 06, 2025 07:00 ET | Source: Entrada Therapeutics, Inc.

Entrada Therapeutics Reports Second Quarter 2025 Financial Results

Entrada Therapeutics reports financial results for the second quarter ended June 30, 2025, and highlights recent business updates.
July 30, 2025 09:00 ET | Source: Muscular Dystrophy Association

Registration Now Open for the 2026 MDA Clinical & Scientific Conference Where Global Leaders in Neuromuscular Disease Research & Care Unite to Drive the Next Breakthroughs March 8-11 in Orlando, FL

New York, July 30, 2025 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA), leader and innovator of the largest global gathering of the neuromuscular disease community, announced today...
May 28, 2025 07:00 ET | Source: Entrada Therapeutics, Inc.

Entrada Therapeutics Receives Authorization in the European Union to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in Patients Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping

Entrada Therapeutics announces that it has received authorization in the European Union to initiate its ELEVATE-45-201 clinical study.